StrideBio, Inc. is a gene therapy company headquartered in Durham, NC. StribeBio creates and develops novel adeno-associated viral (AAV) vector technologies for the treatment of pre-existing neutralizing antibodies in patients. The company’s technical approach offers the potential to enable a wide range of applications including gene addition, gene silencing and gene editing modalities for a wide range of diseases, including rare genetic diseases.